Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Analysts

Shares of Novavax, Inc. (NASDAQ:NVAX - Get Free Report) have received an average recommendation of "Hold" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $19.00.

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a research note on Friday, May 9th. TD Cowen upgraded shares of Novavax to a "hold" rating in a report on Thursday, February 27th. Finally, BTIG Research assumed coverage on shares of Novavax in a report on Friday, February 28th. They set a "buy" rating and a $19.00 price objective on the stock.

Hedge Funds Weigh In On Novavax

Hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC boosted its position in Novavax by 73.9% in the 3rd quarter. Barclays PLC now owns 709,579 shares of the biopharmaceutical company's stock worth $8,961,000 after purchasing an additional 301,627 shares in the last quarter. SG Americas Securities LLC boosted its position in Novavax by 0.4% in the 4th quarter. SG Americas Securities LLC now owns 1,158,967 shares of the biopharmaceutical company's stock worth $9,318,000 after purchasing an additional 4,691 shares in the last quarter. Shah Capital Management boosted its position in Novavax by 13.6% in the 4th quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company's stock worth $89,637,000 after purchasing an additional 1,333,305 shares in the last quarter. KBC Group NV boosted its position in Novavax by 97.0% in the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 3,917 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Novavax by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,965 shares of the biopharmaceutical company's stock worth $273,000 after purchasing an additional 3,174 shares in the last quarter. Institutional investors and hedge funds own 53.04% of the company's stock.

Novavax Trading Up 2.5%

Shares of NVAX opened at $7.29 on Friday. The firm has a market capitalization of $1.18 billion, a P/E ratio of -3.23, a P/E/G ratio of 2.85 and a beta of 3.21. Novavax has a 12-month low of $5.01 and a 12-month high of $23.86. The firm has a fifty day moving average price of $6.63 and a 200-day moving average price of $7.85.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share for the quarter, topping analysts' consensus estimates of $0.71 by $2.22. The business had revenue of $666.66 million during the quarter, compared to analysts' expectations of $204.08 million. During the same period last year, the company earned ($1.05) earnings per share. The firm's revenue was up 610.3% compared to the same quarter last year. Analysts predict that Novavax will post -1.46 earnings per share for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.